Top

Published in:

01-05-2011 | Original Article

Feasibility and Toxicity of Concomitant Radio/Immunotherapy with MabThera (Rituximab^®) for Patients with Non-Hodkin's Lymphoma

Results of a Prospective Phase I/II Study

Authors: Alfred Haidenberger*, Dr. Sabine Fromm-Haidenberger*, Alexander de Vries, Bela-Andre Popper, Michael Steurer, Ira Skvortsova, Johanna Kantner, Eberhard Gunsilius, Peter Lukas

Published in: Strahlentherapie und Onkologie | Issue 5/2011

Title: Feasibility and Toxicity of Concomitant Radio/Immunotherapy with MabThera (Rituximab®) for Patients with Non-Hodkin's Lymphoma
Results of a Prospective Phase I/II Study
Authors: Alfred Haidenberger*
Dr. Sabine Fromm-Haidenberger*
Alexander de Vries
Bela-Andre Popper
Michael Steurer
Ira Skvortsova
Johanna Kantner
Eberhard Gunsilius
Peter Lukas
Publication date: 01-05-2011
Publisher: Urban and Vogel
Published in: Strahlentherapie und Onkologie / Issue 5/2011
Print ISSN: 0179-7158
Electronic ISSN: 1439-099X
DOI: https://doi.org/10.1007/s00066-011-2169-y

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Feasibility and Toxicity of Concomitant Radio/Immunotherapy with MabThera (Rituximab^®) for Patients with Non-Hodkin's Lymphoma

Results of a Prospective Phase I/II Study

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Please log in to get access to this content

Other articles of this Issue 5/2011

Adjuvant Low Single Dose Cisplatin-based Concurrent Radiochemotherapy of Oral Cavity and Oropharynx Carcinoma

Retrospective, Monocentric Analysis of Late Effects after Total Body Irradiation (TBI) in Adults

Prostate Cancer Radiotherapy in Austria

Iodine-125 Orbital Brachytherapy with a Prosthetic Implant In Situ

Simple Proposal for Dosimetry with an Elekta iViewGTTM Electronic Portal Imaging Device (EPID) Using Commercial Software Modules

Prognostic Value of Radiobiological Hypoxia during Fractionated Irradiation for Local Tumor Control